Sugi Predict

Sugi Predict / Compounds / SCHEMBL7943522

SCHEMBL7943522

SCHEMBL7943522

CCC1CCC(N2CCN(C)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NCF1 P14598 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ OPRM1 P35372 4/20 0.33
▸ OPRL1 P41146 4/20 0.33
▸ OPRK1 P41145 1/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ PIM1 P11309 1/20 0.33
▸ L3MBTL3 Q96JM7 1/20 0.33
▸ ACHE P22303 1/20 0.32
▸ RAD52 P43351 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22570156 1.00 MEN1 (0.45) MEN1KMT2ANCF1HRH3KDM4E
SCHEMBL22570309 1.00 MEN1 (0.45) MEN1KMT2ANCF1HRH3KDM4E
SCHEMBL22175015 0.91 KMT2A (0.50) MEN1KMT2AKDM4EALDH1A1ALOX15
SCHEMBL24619026 0.91 KMT2A (0.50) MEN1KMT2AKDM4EALDH1A1ALOX15
SCHEMBL81624 0.83 L3MBTL1 (0.39) NCF1HRH3KDM4EALDH1A1ALOX15
SCHEMBL23384365 0.83 NCF1 (0.46) MEN1KMT2ANCF1KDM4EALDH1A1
SCHEMBL11919059 0.83 NCF1 (0.46) MEN1KMT2ANCF1KDM4EALDH1A1
SCHEMBL12465280 0.82 MEN1 (0.44) MEN1KMT2AOPRM1OPRL1L3MBTL1
SCHEMBL23653473 0.82 MEN1 (0.44) MEN1KMT2AKDM4EALDH1A1ALOX15
SCHEMBL12605203 0.81 MEN1 (0.42) MEN1KMT2ANCF1HRH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof Beijing Adamadle Biotechnology Limited Liability Company (CN) 2022-06-07 — — US disclosed
US-20200262812-A1 4, 5, 6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN MEDICINES YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-08-20 — — US disclosed
WO-2020140052-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. (US) 2020-07-02 — — WO disclosed
US-20200087296-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Adamadle Biotechnology Limited Liability Company (CN) 2020-03-19 — — US disclosed
US-10172858-B2 Combination pharmaceutical compositions and uses thereof INTELLIKINE LLC (US) 2019-01-08 — — US disclosed
US-9908884-B2 EGFR inhibitors and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-03-06 — — US disclosed
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2014-03-13 — — US disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 — — US disclosed
US-8507484-B2 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-08-13 — — US disclosed
US-8507484-B2 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-08-13 — — US disclosed
US-8394805-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-03-12 — — US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 — — US disclosed
US-20110098282-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-28 — — US disclosed
WO-2010015803-A1 DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R & D MANAGEMENT CO. LTD (JP) 2010-02-11 — — WO disclosed
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA KIRIN CO., LTD. (JP) 2007-09-13 — — US disclosed
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA KIRIN CO., LTD. (JP) 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073627-A1 BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 MEN1 231/4885KMT2A 1859/4885NCF1 1517/4885
US-20200262812-A1 4, 5, 6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN MEDICINES CYP3A4, CYP4B1, CYP3A7 MEN1 899/4885KMT2A 3818/4885NCF1 3356/4885
US-10172858-B2 Combination pharmaceutical compositions and uses thereof CDC25C, CCNC, CDC25B MEN1 1651/4885KMT2A 1706/4885NCF1 1341/4885
US-20110098282-A1 NEW COMPOUNDS BRDT, AURKAIP1, ABCG2 MEN1 2557/4885KMT2A 3466/4885NCF1 938/4885
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases MPO, MSR1, NR4A3 MEN1 4203/4885KMT2A 3038/4885NCF1 5/4885
US-20200087296-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF WEE1, WEE2, EGFR MEN1 2417/4885KMT2A 3524/4885NCF1 1452/4885
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof WEE1, WEE2, EGFR MEN1 2417/4885KMT2A 3524/4885NCF1 1452/4885
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 MEN1 349/4885KMT2A 2057/4885NCF1 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.